| Criteria |
Approval Period |
Management of the manifestations of schizophrenia or related psychotic disorders in:
1. Patients who have tried oral risperidone
PLUS
at least one other antipsychotic agent
PLUS
continue to be inadequately controlled at maximally-tolerated doses |
Indefinite
|
OR |
2. Patients who are currently receiving a conventional depot antipsychotic
PLUS
experiencing significant side effects such as Extrapyramidal symptoms or Tardive dyskinesia |
Indefinite |
OR |
3. Patients with a history of non-adherence as evidenced by outcomes such as repeated hospitalizations |
Indefinite |
